GlassScriptPhysician profile
Michael Stanley Siuta
NPI 1740274281
$11,722.90
in general payments reported to CMS, 2019-2025
42 companies · $1,906 in 2025
The $1,906 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $1,200 · 2021: $1,631 · 2022: $1,782 · 2023: $1,822 · 2024: $1,688 · 2025: $1,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,407 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,407.49 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,786.08 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $1,255.49 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,004.33 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $953.09 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ironwood Pharmaceuticals, INC | $501.42 | 2019-2024 | Linzess |
| Pfizer INC. | $445.59 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $395.49 | 2019-2025 | Ocaliva |
| Amgen INC. | $374.47 | 2020-2023 | Avsola, Amjevita |
| Genzyme Corporation | $345.76 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $284.19 | 2019-2024 | Dificid, Zinplava |
| Redhill Biopharma INC. | $176.17 | 2020-2022 | |
| Ardelyx, INC. | $170.65 | 2022-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $155.52 | 2025 | Rezdiffra |
| Celgene Corporation | $149.32 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $148.72 | 2020-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $141.51 | 2024-2025 | Iqirvo, Bylvay |
| Fresenius Kabi USA, LLC | $137.62 | 2023-2024 | Idacio |
| Braintree Laboratories, INC. | $125.13 | 2019-2023 | Sutab |
| Qol Medical, LLC | $117.78 | 2019-2024 | Sucraid |
| Gilead Sciences, INC. | $111.21 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $103.90 | 2022-2024 | Dupixent |
| Daiichi Sankyo INC. | $99.26 | 2019-2024 | Injectafer |
| Ferring Pharmaceuticals INC. | $83.41 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $69.79 | 2024-2025 | Vowst |
| Organon LLC | $66.63 | 2021-2025 | Hadlima, Renflexis |
| Alnylam Pharmaceuticals INC. | $51.70 | 2023-2024 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.43 | 2023 | Cyltezo |
| Lilly USA, LLC | $49.53 | 2024 | Omvoh |
| Romark Laboratories, Lc | $49.47 | 2019 | |
| Phathom Pharmaceuticals, INC. | $44.50 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $44.08 | 2020-2025 | |
| Ucb, INC. | $41.02 | 2020 | |
| Shire North American Group INC | $33.56 | 2019 | |
| Invivyd INC | $32.52 | 2025 | Pemgarda |
| Medtronic, INC. | $20.74 | 2021 | |
| Shionogi INC | $19.52 | 2020 | |
| Enterra Medical, INC. | $17.30 | 2023 | |
| Dova Pharmaceuticals | $15.02 | 2019 | |
| Capsovision, INC. | $14.72 | 2024 | Capsocam Plus |
| Endogastric Solutions, INC | $13.94 | 2024 | Esophyx |
| Horizon Therapeutics Plc | $12.08 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Siuta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.